Core Viewpoint - The strategic partnership between SHUFTI and Tianjin Huazhong Medical Aesthetic Hospital marks a significant step in the implementation of SHUFTI's dual-driven model of "product strength × system empowerment" in the North China market, focusing on "cell-level rejuvenation repair" to provide safer and more effective skin rejuvenation solutions for consumers [1] Group 1: Collaboration and Product Development - SHUFTI and Tianjin Huazhong will jointly launch the "Light Needle Combined Treatment Repair Program," which utilizes SHUFTI's star product, the Hidden Age Needle, in conjunction with water light and phototherapy treatments, achieving a significant reduction in post-operative pigmentation issues and doubling the treatment effectiveness for problematic skin [2] - The program incorporates a comprehensive 28-day post-operative maintenance product line developed based on the "Five-Dimensional Balance" concept, managing all aspects from cleansing to skincare and protection to enhance daily skincare efficacy [2] Group 2: System Empowerment and Growth - SHUFTI's "Skin Department Positive Growth System" injects comprehensive growth momentum into Tianjin Huazhong by enhancing customer loyalty through item operation systems and effect management systems, leading to increased customer satisfaction and long-term repurchase rates [5] - The "Professional Replication System" addresses the issue of insufficient professional capabilities within the institution by providing online and offline training courses, resulting in a rapid short-term improvement in operational efficiency [5] Group 3: Industry Transformation and Future Plans - The partnership represents a broader industry value transformation, with SHUFTI's General Manager emphasizing that their system empowerment is not merely a "toolkit" but a comprehensive reconstruction of the entire chain from product design to customer operation, helping skin care institutions transition from a "traffic battlefield" to a "value blue ocean" [6] - SHUFTI plans to deepen its regional strategic layout and expand its national market presence through a "City Benchmark Program," believing that combining product expertise with operational empowerment will drive sustainable growth in China's medical aesthetics industry [6]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $39.4 million, a decline of 17.3% from Q1 2024, with adjusted EBITDA at $3.8 million and a margin of 9.5%, down from $7.3 million and 15.4% in the prior year [7][21][24] - Same store revenue declined approximately 24% year-over-year, consistent with expectations and Q4 trends [9][21] - Average revenue per case was $12,799, slightly higher than the first quarter of 2024 [21] Business Line Data and Key Metrics Changes - The decline in revenue was primarily driven by lower case volume, with cases down 17.9% to 3,070 [21] - Cost of service decreased by $2.1 million compared to the prior year, but as a percentage of revenue increased to 40.5% from 37.9% [22][23] - Customer acquisition cost for the quarter was $3,130 per case, up from $2,990 in the prior year quarter [24] Market Data and Key Metrics Changes - The percentage of patients using financing to pay for procedures was 44%, down from 50% in Q4 2024 [22] - The company operates in a challenging macroeconomic environment, impacting consumer spending and case volumes [19][50] Company Strategy and Development Direction - The company is focused on stabilizing performance and laying the foundation for long-term growth, with a plan to improve marketing efficiency and operational rigor [6][19] - New services, such as a skin tightening procedure pilot, are being introduced to tap into more consumer demand [16] - The company is reallocating marketing spend to proven strategies, including search engine and social media marketing, while testing new areas like online video [15][44] Management's Comments on Operating Environment and Future Outlook - Management remains confident in the business's ability to return to growth and improve profitability, despite current challenges [20][19] - The guidance for fiscal 2025 revenue is projected between $160 million and $170 million, with adjusted EBITDA between $16 million and $18 million [18][26] - The company is closely monitoring consumer behavior and economic conditions, particularly inflationary pressures and changes in sentiment [19][50] Other Important Information - The company is focused on reducing leverage to historical levels, with a leverage ratio of 3.76 times as of March 31, 2025 [25] - Cash flow from operations for the quarter was $900,000, down from $3.4 million in Q1 2024 [26] Q&A Session Summary Question: Can you speak to some of the specific cost savings that you saw in the quarter? - Management noted that significant cost savings were achieved through workforce changes, targeting $3 million in savings for the year [29] Question: What is the potential margin you think you can achieve on $160 million to $170 million of revenues? - Management expects to approach long-term EBITDA margins of around 30% as revenue trends improve [31] Question: Have you seen any improvement in the rate of conversion to cases? - Management indicated that the time to book cases remains elongated due to macroeconomic pressures, but lead volume growth is encouraging [38] Question: What does the low end versus the high end of your guidance assume for the current macro environment? - The low end assumes further moderation in consumer spending, while the high end incorporates benefits from initiatives like financing options [49] Question: When will the new financing options roll out? - The rollout of expanded financing options is expected by the end of Q2 2025 [54]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $39.4 million, a decline of 17.3% from Q1 2024, with adjusted EBITDA at $3.8 million and a margin of 9.5%, down from $7.3 million and 15.4% in the prior year [7][21][25] - Same store revenue decreased approximately 24% year-over-year, consistent with expectations [9][21] - Average revenue per case was $12,799, slightly higher than the previous year [21] Business Line Data and Key Metrics Changes - The decline in revenue was primarily driven by lower case volumes, with cases down 17.9% to 3,070 [21] - Cost of service decreased by $2.1 million compared to the prior year, but as a percentage of revenue increased to 40.5% from 37.9% due to fixed costs [22][23] - Customer acquisition cost rose to $3,130 per case from $2,990 in the prior year, driven by decreased case volumes [25] Market Data and Key Metrics Changes - The percentage of patients using financing for procedures was 44%, down from 50% in the previous quarter [22] - The company operates in a challenging macroeconomic environment, impacting consumer spending and case volumes [6][19] Company Strategy and Development Direction - The company is focused on stabilizing performance and laying the foundation for long-term growth, with a strategic emphasis on cost discipline, marketing efficiency, and operational rigor [6][7] - New marketing strategies have been implemented, reallocating spend to effective channels such as search engine marketing and social media [15][46] - A pilot for a new skin tightening procedure is being launched, expected to broaden consumer reach and create a new revenue stream [16] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the softening consumer environment and internal challenges but remains confident in the steps taken to reposition the business for sustained success [6][19] - The company expects fiscal 2025 revenue in the range of $160 million to $170 million and adjusted EBITDA between $16 million and $18 million, reflecting current economic conditions [18][27] - Management is closely monitoring consumer behavior and inflationary pressures, which could impact discretionary spending [19] Other Important Information - The company is committed to reducing leverage to historical levels and is in compliance with all covenants under its credit agreement [26] - Cash flow from operations for the quarter was $900,000, down from $3.4 million in the prior year [27] Q&A Session Summary Question: Can you speak to some of the specific cost savings that you saw in the quarter? - Management noted significant cost savings from workforce changes, targeting $3 million in savings for the year [30] Question: What is the potential margin you think you can achieve on $160 million to $170 million of revenues? - Management expects to approach long-term EBITDA margins of around 30% as revenue trends improve [32] Question: Have you seen any improvement in the rate of conversion to cases? - Management indicated that the time to book cases remains elongated due to macroeconomic pressures, but lead volumes are growing [40] Question: What does the low end versus the high end of your guidance assume for the current macro? - The low end assumes further moderation in consumer spending, while the high end incorporates benefits from new initiatives [52] Question: When will the new financing options roll out? - The rollout is expected by the end of Q2, aimed at providing consumers with more flexible payment options [56]

Core Viewpoint - ST Meigu's restructuring has attracted significant interest from investors, with Tianjin Xinmeitong and Hubei Jiuzhou Industrial Park Management Company set to become the main investors, aiming to revitalize the company amid its financial difficulties [1][4]. Group 1: Restructuring Details - Tianjin Xinmeitong and Hubei Jiuzhou are the selected investors for ST Meigu's restructuring, with Jiuzhou expected to become the controlling shareholder post-restructuring [1]. - Jiuzhou plans to invest 673.2 million yuan to acquire 360 million shares at a price of 1.87 yuan per share, which is 50% of the market reference price [2]. - Tianjin Xinmeitong will also acquire 100 million shares at the same price, totaling 187 million yuan [2]. Group 2: Financial Performance and Challenges - ST Meigu is facing significant financial losses, with a projected net loss of 320 million to 450 million yuan for 2024 [4]. - The company has had its bank accounts frozen due to litigation and overdue debts, leading to additional trading risks [4]. - Despite these challenges, the medical beauty service segment has shown strong revenue, contributing 58.82% of the total revenue in the first half of 2024 [5]. Group 3: Strategic Implications - Jiuzhou's investment aligns with its long-term strategic goals, particularly in the medical beauty sector, which has seen rapid growth [5]. - The medical beauty business of Jiuzhou reported a sales revenue of 342 million yuan in 2023, a 103.06% increase year-on-year [5]. - The restructuring process remains uncertain, with potential risks of court rejection or delisting by the end of 2025 [5].

Financial Data and Key Metrics Changes - In Q4 2024, total revenue was RMB 369.2 million, a decrease of 5.5% year-over-year, primarily due to a decline in revenue from So-Young Prime [23] - Net loss attributable to So-Young was RMB 607.6 million, compared to a net income of RMB 17.5 million in the same period last year [27] - Non-GAAP net loss was RMB 53.2 million, compared to a non-GAAP net income of RMB 35.7 million in the same period of 2023 [27] - For the full year 2024, total revenues were RMB 1.47 billion, down 2.1% year-over-year [28] Business Line Data and Key Metrics Changes - Revenue from aesthetic treatment services surged to RMB 81.3 million in Q4, up 701.6% year-over-year, driven by the expansion of the aesthetic center business [23] - Sales of medical products and maintenance services were RMB 86.2 million, down 15.2% year-over-year, primarily due to a decrease in order volume for medical equipment [23] - Total operating expenses were RMB 815.2 million, up 216.2% year-over-year, with significant increases in sales and marketing expenses [25] Market Data and Key Metrics Changes - The total number of verified paid aesthetic treatments surpassed 81,500, with over 38,000 verified paid visits recorded [10] - The aesthetic center network demonstrated strong growth, with 19 clinics opened across nine core cities, and 11 centers achieving positive monthly operating cash flow in December [9] Company Strategy and Development Direction - The company is focused on vertical integration within the aesthetic medical industry, leveraging its user base and supply chain capabilities to drive growth [7][32] - The aesthetic center business is seen as a new growth engine, with plans to replicate successful models across more locations [14] - The company aims to establish a leading position in the market by expanding its aesthetic center network, which currently has a low penetration rate in China [51][52] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential of the aesthetic center network, citing the low market share of chain clinics in China [51] - The company anticipates steady improvement in financial performance as market conditions stabilize and the aesthetic center business continues to expand [32] - Management highlighted the importance of maintaining a balance between growth and profitability while enhancing financial resilience [67] Other Important Information - The company recorded a one-time goodwill impairment charge of RMB 540 million for its subsidiary, impacting the bottom line [7] - Cash and cash equivalents, along with term deposits and short-term investments, totaled RMB 1.25 billion as of December 31, 2024, indicating a robust cash position [30] Q&A Session Summary Question: What are the latest developments in merchant support during the industry consolidation period? - Management noted that as industry consolidation accelerates, large chain institutions are gaining market share, and So-Young is optimizing its platform to empower aesthetic institutions and improve user experience [36][37] Question: How does the company adapt its strategies for centers at different stages of development? - Management explained that differentiated operational strategies are implemented at various phases to ensure optimal performance and enhance brand influence [44][46] Question: Can the aesthetic center business maintain growth? - Management affirmed that the aesthetic center network has the capability for sustained growth, citing the low penetration rate of chain clinics in China as an opportunity for expansion [51][52] Question: What is the strategy for the upstream business? - Management discussed the integration of Miracle Laser into So-Young's upstream business, focusing on product innovation and enhancing collaboration to drive sustainable growth [58][60] Question: Could management share more insights into the company's financial outlook? - Management emphasized a commitment to sustainable growth through vertical integration, balancing growth with profitability, and maintaining financial resilience [67]